-
Product Name
RBM39 antibody
- Documents
-
Description
RBM39 Rabbit Polyclonal antibody. Positive IHC detected in human pancreas tissue. Positive WB detected in HEK-293T cells, human skeletal muscle tissue, mouse kidney tissue. Observed molecular weight by Western-blot: 60-70kd
-
Tested applications
ELISA, IHC, WB
-
Species reactivity
Human,Mouse,Rat; other species not tested.
-
Alternative names
CAPER antibody; CAPERalpha antibody; CC1.3 antibody; DKFZp781C0423 antibody; FLJ44170 antibody; fSAP59 antibody; HCC1 antibody; RBM39 antibody; RNA binding motif protein 39 antibody; RNA binding protein 39 antibody; RNPC2 antibody; Splicing factor HCC1 antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
This antibody was obtained by immunization of RBM39 recombinant protein (Accession Number: NM_184234). Purification method: Antigen affinity purified.
-
Clonality
Polyclonal
-
Formulation
PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
-
Storage instructions
Store at -20℃. DO NOT ALIQUOT
-
Applications
Recommended Dilution:
WB: 1:500-1:5000
IHC: 1:20-1:200
-
Validations
Immunohistochemical of paraffin-embedded human pancreas using Catalog No:114611(RBM39 antibody) at dilution of 1:50 (under 10x lens)
Immunohistochemical of paraffin-embedded human pancreas using Catalog No:114611(RBM39 antibody) at dilution of 1:50 (under 40x lens)
HEK-293T cells were subjected to SDS PAGE followed by western blot with Catalog No:114611(RBM39 Antibody) at dilution of 1:1000
-
Background
RBM39, also named as HCC1 or RNPC2, is a 530 amino acid protein, which contains three RRM (RNA recognition motif) domains and belongs to the splicing factor SR family. RBM39 is widely expressed in various tissues and with highly expression in pancreas, skeletal muscle, lung and brain. RBM39 is a transcriptional coactivator for steroid nuclear receptors ESR1/ER-alpha and ESR2/ER-beta, and JUN/AP-1. RBM39 may be involved in pre-mRNA splicing process.
-
References
- Neumann M, Valori CF, Ansorge O. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta neuropathologica. 124(5):705-16. 2012.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"